Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05106725 · ClinicalTrials.gov registry record
Wearable Devices and Biomarkers Project (Healthiomics)
A clinical trial of Brain Cancer and Neurological Disorder, sponsored by CureScience.
- Recruiting
- Registry status
- 3,500
- Enrollment target
- 1
- Study location
NCT05106725 is a study of Brain Cancer and Neurological Disorder that is actively recruiting participants, run by CureScience. The registered enrollment target is 3,500 participants, above the 433-participant average among 47 other Brain Cancer trials with a reported enrollment target (708% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05106725, a study of Brain Cancer and Neurological Disorder, is actively recruiting participants, sponsored by CureScience.
- RECRUITING
- Registry status
- 3,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect clinical data, biological specimens (e.g., blood, tumor, cerebrospinal fluid, urine sample, etc.), and digital health data from patients with tumors, cancer and/or neurological disorders in order to perform research studies that could advance patient care. By collecting these specimens, the investigators plan to create and maintain a biorepository to make data and specimens available to collaborating investigators performing research to discover predictive biomarkers, patterns of care, and personalized treatments that could directly improve the care of our patients through focused proof-of-concept clinical trials.
Conditions Studied
Study Locations (1)
California
- CureScience Institute - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,500 participants |
| Start Date | 2021-10-11 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05106725
The ClinicalTrials.gov registry entry for NCT05106725 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 433-participant average among 47 other Brain Cancer trials with a reported enrollment target (708% higher). The listed sponsor is CureScience, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Brain Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05106725 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05106725 about?
NCT05106725 is a clinical study titled "Wearable Devices and Biomarkers Project (Healthiomics)". The purpose of this study is to collect clinical data, biological specimens (e.g., blood, tumor, cerebrospinal fluid, urine sample, etc.), and digital health data from patients with tumors, cancer and/or neurological disorders in order to perform research studies that could advance patient care. By ...
What is the current status of trial NCT05106725?
This trial is currently recruiting. The enrollment target is 3,500 participants. The study started on 2021-10-11. Estimated completion is 2025-12-31.
What conditions does trial NCT05106725 study?
This clinical trial studies the following conditions: Brain Cancer, Neurological Disorder, Neurological Cancer.
Who is sponsoring clinical trial NCT05106725?
This trial is sponsored by CureScience, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05106725 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.